Indeed, being selectivefor NKCC1, this chemical class has a safer pharmacological profilefor chronic use to treat brain disorders because it is devoid of unwanteddiuretic effects (caused by inhibition of the isoform NKCC2 in thekidney, as in the case of bumetanide). This evidence concerns the gene SLC12A2 and brain disorder.